Impact of the antiphospholipid syndrome on complications during pregnancy

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 6, 2006, Pages 486-492

  Schleussner, E ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Antiphospholipid syndrome; Fetal loss; Low dose aspirin; Low molecular weight heparin; Pregnancy outcome; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CERTOPARIN; CLEXANE 40; COUMARIN ANTICOAGULANT; DALTEPARIN; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; MONOEMBOLEX; NADROPARIN; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; PROCOAGULANT; PROTEIN C; TINZAPARIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BRAIN HEMORRHAGE; CELL ACTIVATION; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBRYOTOXICITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FETAL WELL BEING; HEPARINIZATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LOW BIRTH WEIGHT; LOW DRUG DOSE; MATERNAL TREATMENT; MONOCYTE; MONOTHERAPY; NEWBORN DISEASE; PLACENTA DEVELOPMENT; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DEVELOPMENT; RECURRENT DISEASE; REVIEW; SECOND TRIMESTER ABORTION; SECONDARY PREVENTION; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TROPHOBLAST; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 34047227120     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096046     Document Type: Review

References (48)

1. Harris EN: Syndrome of the black swan. Br J Rheumatol 1987;26:324-326.
2. Girling J, deSwiet M: Acquired thrombophilia. Baillieres Clin Obstet Gynaecol 1997;11:447-462.
3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311.
4. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-443.
5. Bertolaccini ML, Khamashta MA, Hughes G: Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005;1:40-46.
6. Bertolaccini ML, Khamashta MA: Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 2006;15:172-178.
7. Bizzarro N, Tonutti E, Villalta D, Tampona M, Bozzoli R: Prevalence and clinical correlation of antiphospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005;129:61-68.
8. Greaves M: Antiphospholipid syndrome: clinical manifestations and management. Thromb Res 2005; 115S:27-30.
9. Greaves M, Cohen H, Machin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715.
10. Petri M: Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-151.
11. Juby AG, Davis P: Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998;21:4-11.
12. Olech E, Merrill JT: The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep 2006;8:100-108.
13. Henly JG: Antiphospholipid syndrome: an overview. CMAJ 2003;168:1675-1682.
14. Lim W, Crowther MA, Eikelboom JW: Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-1057.
15. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH: Anticardiolipin antibodies and the risk for ischemic stroke and thrombosis. Ann Int Med 1992;117:997-1002.
16. Schulman S, Svenungsson E, Granquist S, the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-338.
17. Carhuapoma JR Mitsias P, Levine SR: Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28:2363-2369.
18. Gomez-Puerta JA; Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado M, Hughes GR, Khamashta MA: Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005;84:225-230.
19. Empson M, Lassere M, Craig J, Scott J: Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135-144.
20. Mtiraouia N, Borgia L, Hizema S, Nsiria B, Finanb R, Gris JC, Almawi WT, Mahjouba W: Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005;119:164-170.
21. Rai RS, Clifford K, Cohen H, Regan L: High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301-3304.
22. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW: Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489-493.
23. Bocciolone L, Meroni P, Parazrini F, Tincani A, Radici E, Tarantini M, Rossi E, Bianchi C, Mezzanotte C, D'Angelo A: Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstet Gynecol Scand 1994;73:389-392.
24. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GDO, Walker ID, Greaves M, Brenkel I, Regan L, Greer I, for the Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study: Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005;132:171-196.
25. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-1048.
26. Kupferminc M: Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003;1:111-163.
27. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K: Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86:1-9.
28. Galli M: Pathogenesis of antiphospholipid syndrome. Thromb Res 2005;115(suppl 1)1:103-107.
29. Stalc M, Poredos P, Tomsic M, Sebestjen M, Kveder T: Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006;118:455-461.
30. Salafia CM, Cowchock FS: Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 1997;14:435-441.
31. Van Horn JT, Craven C, Ward K, Branch DW, Silver RM: Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004;25:642-648.
32. Rand J, Van Eerden P, Wu XX, Chazotte C: Defective annexin a5 crystallization: a mechanism for pregnancy losses in the antiphospholipid syndrome. Thromb Res 2005;115(suppl 1):77-81.
33. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L: Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 2002;17:1067-1071.
34. Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, Huppertz B: Adverse efects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004;192:23-30.
35. Quenby S, Mountfield S, Cartwright JE, Whitley G, Chamley L, Vince G: Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005;83:691-698.
36. Empson M, Lassere M, Craig J, Scott J: Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005 Apr 18;(2):CD002859.
37. Ginsberg JS, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 1998;114(suppl 5):524S-530S.
38. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JWK, Farewell V: Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148-153.
39. Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, Romanini C: Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001;45:174-179.
40. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH: Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-734.
41. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J: Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-690.
42. Mecacci F, Mello G, Prisco D, Mignosa M, Ricci F, Cioni R, Scarselli G, Marchionni M, Paidas M: A comparative study of low dose aspirin and ether prophylactic dalteparin or unfractionated heparin in pregnancies complicated by antiphospolipid antibody syndrome. Eur J Obstet Gynecol Reprod Biol 2006;126:(in press).
43. Greer IA, Nelson-Piercy C: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407.
44. Schleussner E, Westphal J, Seewald HJ: Pregnancy complications by antiphospholipid syndrome - 5 years experiences of an university hospital. Thromb Res 2005;115(suppl 1):140-141.
45. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ: Safety and efficacy of low-molecular weight heparin in pregnant women at risk of venous thromboembolism: prospective cohort study. Thromb Res 2005;115(suppl 1):149.
46. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J, LIVE-ENOX Investigators: Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005;3:227-229.
47. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J: Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004;190:495-501.
48. Bates SM, Greer IA, Hirsh J, Ginsberg JS: Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126;627-644.